Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseSymptoms, Doctors, Treatments, Advances & More
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Overview
Learn About Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Friedemann Paul practices in Goyang, Republic of Korea. Paul is rated as an Elite expert by MediFind in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Their top areas of expertise are Multiple Sclerosis (MS), Transverse Myelitis, Optic Neuritis, and Neuromyelitis Optica.
MN - Neuro MS
Sean Pittock is a Neurologist in Rochester, Minnesota. Dr. Pittock is rated as an Elite provider by MediFind in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. His top areas of expertise are Optic Neuritis, Transverse Myelitis, Neuromyelitis Optica, and Encephalitis.
Patrick Schindler practices in Berlin, Germany. Mr. Schindler is rated as an Elite expert by MediFind in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. His top areas of expertise are Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Neuromyelitis Optica, Transverse Myelitis, and Optic Neuritis.
Summary: The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period. Participants who experience an adjudicated relapse or complete the DB period can enter open-label extension (OLE) period. After the primary clinical cutoff date (CCOD), ...
Summary: The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).